Response to Letter. "Romosozumab and cardiovascular safety- should we learn lessons from Pioglitazone?."

Osteoporos Int. 2022 Jun;33(6):1401-1402. doi: 10.1007/s00198-022-06300-6. Epub 2022 Feb 18.

Authors

Ayako Tominaga¹, Keiji Wada², Ken Okazaki¹, Hideharu Nishi³, Yasushi Terayama³, Yoshiharu Kato⁴

Affiliations

¹ Department of Orthopedic Surgery, Tokyo Women's Medical University, 8-1 Kawadacho Shinjuku-ku, Tokyo, Japan.
² Department of Orthopedic Surgery, Tokyo Women's Medical University, 8-1 Kawadacho Shinjuku-ku, Tokyo, Japan. [email protected].
³ Hasuda Hospital, 1662-1 Negane Hasudashi, Saitama, Japan.
⁴ Kita Shinagawa 3rd Hospital, 3-3-7 Kitashinagawa Shinagawa-ku, Tokyo, Japan.

PMID: 35181822
DOI: 10.1007/s00198-022-06300-6

No abstract available

Publication types

Letter
Comment

MeSH terms

Antibodies, Monoclonal
Bone Density Conservation Agents*
Humans
Osteoporosis*
Pioglitazone

Substances

Antibodies, Monoclonal
Bone Density Conservation Agents
romosozumab
Pioglitazone